Holen Sie sich die Stockscreener-App
0.3531
9.69%
-0.0379
Handel nachbörslich:
.36
0.0069
+1.95%
Schlusskurs vom Vortag:
$0.391
Offen:
$0.3909
24-Stunden-Volumen:
763.24K
Relative Volume:
0.07
Marktkapitalisierung:
$9.00M
Einnahmen:
$357.90K
Nettoeinkommen (Verlust:
$-11.06M
KGV:
-0.3152
EPS:
-1.1201
Netto-Cashflow:
$-11.90M
1W Leistung:
-10.47%
1M Leistung:
+83.71%
6M Leistung:
-67.31%
1J Leistung:
-78.20%
1-Tages-Spanne:
$0.3506
$0.3925
1-Wochen-Bereich:
$0.3496
$0.42
52-Wochen-Spanne:
$0.1593
$1.89
Biorestorative Therapies Inc Stock (BRTX) Company Profile
Firmenname
Biorestorative Therapies Inc
Sektor
Branche
Telefon
(631) 760-8100
Adresse
40 MARCUS DRIVE, MELVILLE
Compare BRTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BRTX
Biorestorative Therapies Inc
|
0.3531 | 9.96M | 357.90K | -11.06M | -11.90M | -1.1201 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biorestorative Therapies Inc Aktie (BRTX) Neueste Nachrichten
BioRestorative Therapies, Inc. Enters Revolving Credit Agreement with Bowery Group LLC – 12% Interest, NASDAQ: BRTX – Minichart - Minichart
BioRestorative Revamps Board Following New Loan Agreement - TipRanks
BioRestorative Therapies Finalizes Executive Agreement with R&D VP - TipRanks
BioRestorative Therapies enters $1 million revolving loan and appoints new directors - Investing.com Nigeria
BioRestorative (NASDAQ: BRTX) sets 3-year deal with R&D leader Silva - Stock Titan
BioRestorative Therapies, Inc. Enters Into $1,000,000 Revolving Loan Agreement With Bowery Group LLC - marketscreener.com
BioRestorative Therapies (NASDAQ: BRTX) adds $1M revolver and installs lender-backed directors - Stock Titan
BRTX Q1 2026 Earnings: Narrowed Loss Beats Estimates as Cash Management ContinuesEarnings Season Outlook - newsline.com
BioRestorative Therapies Inc. (BRTX) Q1 2026 Earnings: Narrowing Losses Drive Strong Stock SurgeRevenue Miss Report - newsline.com
BRTX Stock Price, Quote & Chart | BIORESTORATIVE THERAPIES INC (NASDAQ:BRTX) - ChartMill
BioRestorative Therapies Executive Employment Agreement with Lance Alstodt: Key Terms, Compensation, and Severance Details - Minichart
BioRestorative Therapies Extends Executive Leadership Employment Agreements - TipRanks
BioRestorative Therapies extends employment agreements for Lance Alstodt and Robert Kristal - TradingView
BioRestorative Therapies (BRTX) triples down on stock capacity and inks new CEO, CFO contracts - Stock Titan
BioRestorative Therapies Inc52-Week Cohort - Moomoo
BioRestorative Therapies jumps after completing Phase 2 dosing for lead spine cell therapy - Quiver Quantitative
BioRestorative Therapies stock surges on activist stake By Investing.com - Investing.com South Africa
BioRestorative Therapies stock surges on activist stake - Investing.com
Kaos Capital is urgently seeking a meeting with the Board of Directors of BioRestorative Therapies, Inc. (BioRestorative Therapies) to explore effective ways to unlock shareholder value for the company. - Bitget
Kaos Capital acquires 4.9% stake in BioRestorative Therapies - marketscreener.com
Kaos Capital Acquires 4.9% Stake In Biorestorative Therapies - TradingView
Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX) - marketscreener.com
Press Release: Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX) - Moomoo
Biorestorative Therapies says topline phase 2 data for BRTX-100 expected in Q2 2027 - marketscreener.com
Biorestorative Therapies Says Topline Phase 2 Data For BRTX-100 Expected In Q2 2027 - TradingView
BioRestorative Therapies Completes Patient Dosing in Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease - Quiver Quantitative
Stem cell back pain shot finishes Phase 2, topline data due 2027 - Stock Titan
BioRestorative Therapies Inc. (BRTX) Q1 2026 Earnings: Narrower Loss Surprises, Stock Rises 7.8%Final Results - The Legal Advocate
BRTX Q1 2026 Earnings: Narrowed Loss Surprises, Shares Climb 7.8%Earnings Beat Alert - newsline.com
BioRestorative Therapies (BRTX) Surges 13.66% as Stock Tests Key Resistance at $0.20Corrective Wave - Newser
What makes Biorestorative Therapies (BRTX) a new buy stock - MSN
Biorestorative Therapies, Inc. (BRTX) reports Q1 loss, misses revenue estimates - MSN
Auctus Fund (BRTX) discloses 2.7M-share, 9.9% position including warrants - Stock Titan
What Makes Biorestorative Therapies (BRTX) a New Buy Stock - Yahoo Finance
MSN Money - MSN
Certain Series B Preferred Stock of BioRestorative Therapies, Inc. are subject to a Lock-Up Agreement Ending on 15-MAY-2026. - marketscreener.com
Certain Warrants of BioRestorative Therapies, Inc. are subject to a Lock-Up Agreement Ending on 15-MAY-2026. - marketscreener.com
Certain Options of BioRestorative Therapies, Inc. are subject to a Lock-Up Agreement Ending on 15-MAY-2026. - marketscreener.com
Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
BioRestorative Therapies Inc reports results for the quarter ended December 31Earnings Summary - TradingView
BioRestorative Therapies, Inc. 1Q 2026: Revenue $23.2K, EPS $(0.12) — 10-Q Summary - TradingView
BioRestorative Therapies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
BioRestorative Therapies (BRTX) Q1 2026 loss, cash burn and Nasdaq bid-price risk - Stock Titan
BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals - Sahm
BioRestorative presents data on stem cell-derived exosomes By Investing.com - Investing.com India
BioRestorative presents data on stem cell-derived exosomes - Investing.com UK
Biorestorative Therapies Presents New Preclinical Data on Source-Specific Exosome Functionality and Commercial Applications in Biocosmeceuticals - marketscreener.com
TradingKey - TradingKey
BioRestorative Therapies Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease - Orthopedics This Week
Finanzdaten der Biorestorative Therapies Inc-Aktie (BRTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):